Investigators sound a safety alarm after 2 patients die of heart condition following checkpoint combo
Checkpoint inhibitors like Keytruda and Opdivo quickly achieved legendary status as breakthrough cancer therapies with broad, blockbuster roles to play on the market. But in a new study published in the New England Journal of Medicine, investigators have spotlighted rare cases in which checkpoint patients have died or been afflicted by heart trouble. And there’s evidence that a T-cell driven reaction threatens a very small group of patients taking the drugs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.